Pandorum Technologies bags $18 mn in Series B funding to advance regenerative therapies

The company said it has adopted a distributed manufacturing approach to support different markets.

Pandorum Technologies has raised $18 million in a Series B funding round to advance clinical development and expand market access for its regenerative therapies.

The India and US-based biotechnology firm said the funding will support clinical programmes, manufacturing scale-up and operations across the US ,Japan and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund and the Burman Family, among others.

Bandana Kankani, an advisor and investor at Pandorum, guided the transaction, the company said.

Founded by Tuhin Bhowmick and Arun Chandru, Pandorum develops exosome-based therapies that modify disease processes by reprogramming tissue responses, such as inflammation and fibrosis.

“Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Tuhin Bhowmick, Co-founder and CEO.

“This funding would enable us to translate science into disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair,” he added.

Regenerative medicine

Arun Chandru, co-founder of Pandorum, said regenerative medicine for corneal blindness remains a major unmet need worldwide.

“Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders,” he said.

Pandorum’s clinical work is being led by clinicians, including Dr Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital, New Delhi and Dr Shigeru Kinoshita of Kyoto Prefectural University of Medicine.

Other collaborators include Dr Ramez Haddadin and Dr Satish Nadig from Northwestern Medicine in Chicago.

The company said it has adopted a distributed manufacturing approach to support different markets.

This includes a contract development and manufacturing partnership with AGC Biologics in Italy for the US and European markets.

Pandorum has also partnered with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region.

The company said it is exploring manufacturing and commercial partnerships in the Middle East.

Pandorum’s initial focus is on ocular surface diseases, including Stevens–Johnson Syndrome and Neurotrophic Keratitis.

Its lead candidate, Kuragenx, has received Orphan Drug Designation from the US Food and Drug Administration.

The company said it is also expanding its platform to address inflammatory and degenerative conditions affecting the lung, liver, and nervous system.

(With inputs from BL intern Tejaswini S)

Published on February 9, 2026